{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:00:57Z","timestamp":1794412857017,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Patients with BRAF V600E-mutated\/microsatellite stable (MSS) metastatic colorectal cancer (mCRC) are associated with a poor prognosis. Backline treatment has minimal efficacy. Multi-target inhibitors of the RAS-RAF-MEK signaling pathway combined with PD-1 monoclonal antibody may be a promising strategy for BRAF V600E-mutated mCRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This prospective phase I trial enrolled patients to explore tolerability and safety of the VCC regimen in previously treated patients with BRAF V600E-mutated\/MSS mCRC. Enrolled patients treated with VCC therapy every 2 weeks (cetuximab 500mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ; camrelizumab 200\u00a0mg; vemurafenib 960\u00a0mg orally once daily). Adverse events and efficacy were monitored and recorded throughout the administration and follow-up period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This trial enrolled 12 eligible patients. Total 2 patients had DLT: one had grade 3 thrombocytopenia and immune myocarditis, another had grade 3 vaginal bleeding. Adverse events (AEs) of grade 3 or higher occurred in 50% of patients. Grade 3 AEs were mainly drug-related fever (25.0%), drug-related rash (16.7%). Median overall survival (OS) and PFS were 7.19 months and 3.47 months, respectively. The ORR and DCR were 33.3% and 66.7%. One patient achieved CR. three patients achieved PR. An abnormal CD4\/CD8 ratio was associated with a higher risk of progression. Different efficacy of VCC regimen may be attributed to the difference in tumor immune environment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A combination of vemurafenib, cetuximab combined with camrelizumab exhibited manageable adverse reactions and efficacy in BRAF V600E-mutated\/MSS patients with metastatic colorectal cancer who progressed after standard treatment. This is a pilot study and a larger phase II trials is planned to validate the findings. (ClinicalTrials.gov ID: NCT05019534).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-025-07312-6","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:25:20Z","timestamp":1762961120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vemurafenib, cetuximab and camrelizumab in BRAF V600E-mutated\/MSS metastatic colorectal cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Gui-Xia","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Bing","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"7312_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/1078-0432.Ccr-16-0140","volume":"23","author":"D Barras","year":"2017","unstructured":"Barras D, et al. BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res. 2017;23:104\u201315. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0140.","journal-title":"Clin Cancer Res"},{"key":"7312_CR2","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/jco.2015.63.2497","volume":"33","author":"S Kopetz","year":"2015","unstructured":"Kopetz S, et al. Phase II pilot study of Vemurafenib in patients with metastatic BRAF-Mutated colorectal cancer. J Clin Oncol. 2015;33:4032\u20138. https:\/\/doi.org\/10.1200\/jco.2015.63.2497.","journal-title":"J Clin Oncol"},{"key":"7312_CR3","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1002\/cncr.26086","volume":"117","author":"B Tran","year":"2011","unstructured":"Tran B, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623\u201332. https:\/\/doi.org\/10.1002\/cncr.26086.","journal-title":"Cancer"},{"key":"7312_CR4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/s1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306\u201315. https:\/\/doi.org\/10.1016\/s1470-2045(15)00122-9.","journal-title":"Lancet Oncol"},{"key":"7312_CR5","doi-asserted-by":"publisher","unstructured":"Caputo F, et al. BRAF-Mutated colorectal cancer: clinical and molecular insights. Int J Mol Sci. 2019;20. https:\/\/doi.org\/10.3390\/ijms20215369.","DOI":"10.3390\/ijms20215369"},{"key":"7312_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2013.08.024","volume":"50","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer. 2014;50:57\u201363. https:\/\/doi.org\/10.1016\/j.ejca.2013.08.024.","journal-title":"Eur J Cancer"},{"key":"7312_CR7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/s1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard D, et al. Dabrafenib plus Trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17:984\u201393. https:\/\/doi.org\/10.1016\/s1470-2045(16)30146-2.","journal-title":"Lancet Oncol"},{"key":"7312_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/s1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, et al. Encorafenib plus binimetinib versus Vemurafenib or Encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:603\u201315. https:\/\/doi.org\/10.1016\/s1470-2045(18)30142-6.","journal-title":"Lancet Oncol"},{"key":"7312_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/jco.20.02088","volume":"39","author":"J Tabernero","year":"2021","unstructured":"Tabernero J, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-Mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39:273\u201384. https:\/\/doi.org\/10.1200\/jco.20.02088.","journal-title":"J Clin Oncol"},{"key":"7312_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/jco.20.01994","volume":"39","author":"S Kopetz","year":"2021","unstructured":"Kopetz S, et al. Randomized trial of Irinotecan and cetuximab with or without Vemurafenib in BRAF-Mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncology: Official J Am Soc Clin Oncol. 2021;39:285\u201394. https:\/\/doi.org\/10.1200\/jco.20.01994.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"7312_CR11","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1158\/0008-5472.Can-18-0365","volume":"78","author":"TB Shabaneh","year":"2018","unstructured":"Shabaneh TB, et al. Oncogenic BRAF(V600E) governs regulatory T-cell recruitment during melanoma tumorigenesis. Cancer Res. 2018;78:5038\u201349. https:\/\/doi.org\/10.1158\/0008-5472.Can-18-0365.","journal-title":"Cancer Res"},{"key":"7312_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1530\/erc-17-0532","volume":"25","author":"KJ Na","year":"2018","unstructured":"Na KJ, Choi H. Immune landscape of papillary thyroid cancer and immunotherapeutic implications. Endocr Relat Cancer. 2018;25:523\u201331. https:\/\/doi.org\/10.1530\/erc-17-0532.","journal-title":"Endocr Relat Cancer"},{"key":"7312_CR13","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/s0140-6736(20)30934-x","volume":"395","author":"R Gutzmer","year":"2020","unstructured":"Gutzmer R, et al. Atezolizumab, vemurafenib, and Cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395:1835\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(20)30934-x.","journal-title":"Lancet"},{"key":"7312_CR14","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-020-1082-2","volume":"26","author":"R Dummer","year":"2020","unstructured":"Dummer R, et al. Combined PD-1, BRAF and MEK Inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020;26:1557\u201363. https:\/\/doi.org\/10.1038\/s41591-020-1082-2.","journal-title":"Nat Med"},{"key":"7312_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ctrv.2017.11.008","volume":"63","author":"RL Ferris","year":"2018","unstructured":"Ferris RL, et al. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2018;63:48\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2017.11.008.","journal-title":"Cancer Treat Rev"},{"key":"7312_CR16","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.1158\/1078-0432.Ccr-15-2971","volume":"22","author":"S Trivedi","year":"2016","unstructured":"Trivedi S, et al. Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients. Clin Cancer Research: Official J Am Association Cancer Res. 2016;22:5229\u201337. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2971.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"7312_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ccell.2015.06.004","volume":"28","author":"JF Goodwin","year":"2015","unstructured":"Goodwin JF, et al. DNA-PKcs-Mediated transcriptional regulation drives prostate cancer progression and metastasis. Cancer Cell. 2015;28:97\u2013113. https:\/\/doi.org\/10.1016\/j.ccell.2015.06.004.","journal-title":"Cancer Cell"},{"key":"7312_CR18","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1371\/journal.pone.0000326","volume":"2","author":"R Bhat","year":"2007","unstructured":"Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells\u2013enhancement by therapeutic antibodies. PLoS ONE. 2007;2:e326. https:\/\/doi.org\/10.1371\/journal.pone.0000326.","journal-title":"PLoS ONE"},{"key":"7312_CR19","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.21873\/anticanres.10985","volume":"36","author":"L Holubec","year":"2016","unstructured":"Holubec L, Polivka J Jr., Safanda M, Karas M, Liska V. The role of cetuximab in the induction of anticancer immune response in colorectal cancer treatment. Anticancer Res. 2016;36:4421\u20136. https:\/\/doi.org\/10.21873\/anticanres.10985.","journal-title":"Anticancer Res"},{"key":"7312_CR20","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1158\/1078-0432.Ccr-12-2426","volume":"19","author":"RM Srivastava","year":"2013","unstructured":"Srivastava RM, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Research: Official J Am Association Cancer Res. 2013;19:1858\u201372. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-2426.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"7312_CR21","doi-asserted-by":"publisher","first-page":"e1008824","DOI":"10.1080\/2162402x.2015.1008824","volume":"4","author":"R Bellucci","year":"2015","unstructured":"Bellucci R, et al. Interferon-\u03b3-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 2015;4:e1008824. https:\/\/doi.org\/10.1080\/2162402x.2015.1008824.","journal-title":"Oncoimmunology"},{"key":"7312_CR22","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, et al. Improved survival with Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1103782.","journal-title":"N Engl J Med"},{"key":"7312_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, et al. Improved overall survival in melanoma with combined Dabrafenib and Trametinib. N Engl J Med. 2015;372:30\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1412690.","journal-title":"N Engl J Med"},{"key":"7312_CR24","doi-asserted-by":"publisher","unstructured":"Qu W, Wang F, Qin S, Sun Y, Huang C. Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China. Therapeutic Adv Med Oncol. 2024;16. https:\/\/doi.org\/10.1177\/17588359241242607.","DOI":"10.1177\/17588359241242607"},{"key":"7312_CR25","doi-asserted-by":"publisher","unstructured":"Wang F, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol. 2020;13. https:\/\/doi.org\/10.1186\/s13045-020-00886-2.","DOI":"10.1186\/s13045-020-00886-2"},{"key":"7312_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer Institute of the united States, National cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205\u201316. https:\/\/doi.org\/10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"key":"7312_CR27","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, et al. Encorafenib, Binimetinib, and cetuximab in BRAF V600E-Mutated colorectal cancer. N Engl J Med. 2019;381:1632\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1908075.","journal-title":"N Engl J Med"},{"key":"7312_CR28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2021.12.028","volume":"163","author":"Z Wang","year":"2022","unstructured":"Wang Z, et al. Cetuximab and Vemurafenib plus FOLFIRI (5-fluorouracil\/leucovorin\/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): an open-label, single-arm, phase II trial. Eur J Cancer. 2022;163:152\u201362. https:\/\/doi.org\/10.1016\/j.ejca.2021.12.028.","journal-title":"Eur J Cancer"},{"key":"7312_CR29","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","volume":"35","author":"ZY Lin","year":"2024","unstructured":"Lin ZY, et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial. Annals Oncology: Official J Eur Soc Med Oncol. 2024;35:882\u201391. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.015.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"7312_CR30","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and Progression-Free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326:916\u201325. https:\/\/doi.org\/10.1001\/jama.2021.12836.","journal-title":"JAMA"},{"key":"7312_CR31","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/s1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21:832\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(20)30110-8.","journal-title":"Lancet Oncol"},{"key":"7312_CR32","doi-asserted-by":"publisher","unstructured":"Wang F, et al. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China. Chin Clin Oncol. 2020;9. https:\/\/doi.org\/10.21037\/cco.2020.03.08.","DOI":"10.21037\/cco.2020.03.08"},{"key":"7312_CR33","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1038\/s41467-024-50996-5","volume":"15","author":"SJ Sun","year":"2024","unstructured":"Sun SJ, et al. Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation. Nat Commun. 2024;15:6640. https:\/\/doi.org\/10.1038\/s41467-024-50996-5.","journal-title":"Nat Commun"},{"key":"7312_CR34","doi-asserted-by":"publisher","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","volume":"41","author":"T Won","year":"2022","unstructured":"Won T, et al. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. 2022;41:111611. https:\/\/doi.org\/10.1016\/j.celrep.2022.111611.","journal-title":"Cell Rep"},{"key":"7312_CR35","doi-asserted-by":"publisher","unstructured":"Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Investig. 2021;131. https:\/\/doi.org\/10.1172\/jci145186.","DOI":"10.1172\/jci145186"},{"key":"7312_CR36","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","volume":"6","author":"LH Lehmann","year":"2021","unstructured":"Lehmann LH, et al. Clinical strategy for the diagnosis and treatment of immune checkpoint Inhibitor-Associated myocarditis: A narrative review. JAMA Cardiol. 2021;6:1329\u201337. https:\/\/doi.org\/10.1001\/jamacardio.2021.2241.","journal-title":"JAMA Cardiol"},{"key":"7312_CR37","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1186\/s12885-024-13171-z","volume":"24","author":"GX Wei","year":"2024","unstructured":"Wei GX, et al. Clinicopathologic features and treatment efficacy of patients with BRAF V600E-mutated metastatic colorectal cancer: a multi-center real-world propensity score matching study. BMC Cancer. 2024;24:1395. https:\/\/doi.org\/10.1186\/s12885-024-13171-z.","journal-title":"BMC Cancer"},{"key":"7312_CR38","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","volume":"29","author":"J Tian","year":"2023","unstructured":"Tian J, et al. Combined PD-1, BRAF and MEK Inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial. Nat Med. 2023;29:458\u201366. https:\/\/doi.org\/10.1038\/s41591-022-02181-8.","journal-title":"Nat Med"},{"key":"7312_CR39","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12032-014-0198-y","volume":"31","author":"T Xu","year":"2014","unstructured":"Xu T, et al. Prognostic significance of Circulating CD19\u2009+\u2009B lymphocytes in EBV-associated nasopharyngeal carcinoma. Med Oncol (Northwood Lond Engl). 2014;31:198. https:\/\/doi.org\/10.1007\/s12032-014-0198-y.","journal-title":"Med Oncol (Northwood Lond Engl)"},{"key":"7312_CR40","doi-asserted-by":"publisher","unstructured":"Buggert M et al. Multiparametric bioinformatics distinguish the CD4\/CD8 ratio as a suitable laboratory predictor of combined T cell pathogenesis in HIV infection. J Immunol. 2014;192:2099\u2013108 https:\/\/doi.org\/10.4049\/jimmunol.1302596.","DOI":"10.4049\/jimmunol.1302596"},{"key":"7312_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/cmi.2010.56","volume":"8","author":"W Shah","year":"2011","unstructured":"Shah W, et al. A reversed CD4\/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol. 2011;8:59\u201366. https:\/\/doi.org\/10.1038\/cmi.2010.56.","journal-title":"Cell Mol Immunol"},{"key":"7312_CR42","doi-asserted-by":"publisher","first-page":"46653","DOI":"10.18632\/oncotarget.9695","volume":"7","author":"CJ Tao","year":"2016","unstructured":"Tao CJ, et al. A prognostic model combining CD4\/CD8 ratio and N stage predicts the risk of distant metastasis for patients with nasopharyngeal carcinoma treated by intensity modulated radiotherapy. Oncotarget. 2016;7:46653\u201361. https:\/\/doi.org\/10.18632\/oncotarget.9695.","journal-title":"Oncotarget"},{"key":"7312_CR43","doi-asserted-by":"publisher","unstructured":"Bianconi D, et al. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the passionate study, a translational prospective phase II study of capecitabine and Irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. Therapeutic Adv Med Oncol. 2020;12. https:\/\/doi.org\/10.1177\/1758835920928635.","DOI":"10.1177\/1758835920928635"},{"key":"7312_CR44","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3892\/or.2012.1951","volume":"28","author":"C Wang","year":"2012","unstructured":"Wang C, et al. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep. 2012;28:1301\u20138. https:\/\/doi.org\/10.3892\/or.2012.1951.","journal-title":"Oncol Rep"},{"key":"7312_CR45","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12964-023-01151-y","volume":"21","author":"Z Kalaei","year":"2023","unstructured":"Kalaei Z, et al. The prognostic and therapeutic value and clinical implications of fibroblast activation protein-\u03b1 as a novel biomarker in colorectal cancer. Cell Communication Signaling: CCS. 2023;21:139. https:\/\/doi.org\/10.1186\/s12964-023-01151-y.","journal-title":"Cell Communication Signaling: CCS"},{"key":"7312_CR46","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","volume":"25","author":"A Ribas","year":"2019","unstructured":"Ribas A, et al. Combined BRAF and MEK Inhibition with PD-1 Blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019;25:936\u201340. https:\/\/doi.org\/10.1038\/s41591-019-0476-5.","journal-title":"Nat Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07312-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07312-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07312-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:25:21Z","timestamp":1762961121000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07312-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7312"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07312-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved in June 2021 by Chinese Ethics Committee of Registering Clinical Trials (ChiECRCT20210210) and the independent ethics committee of West China Hospital, Sichuan University (approval number: 20221806). The trial is registered at Clinicaltrials.gov (NCT05019534).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors read and consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that them have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1274"}}